Rare Oncology
Too many loved ones live with uncertainty.
Let’s find answers.
Rare oncology is where rare diseases and cancers meet. While some rare tumors are not malignant, their presence and progression are nonetheless devastating for patients. At SpringWorks, we are relentless in the search for answers because people with these often-overlooked conditions can’t wait.
Let’s innovate for the overlooked
Our late-stage rare oncology programs have the potential to be best-in-class treatments for patients with devastating diseases, including desmoid tumors, neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) and low-grade gliomas.
Clinical trials
Late-stage clinical trials are underway to evaluate nirogacestat for patients with desmoid tumors and to evaluate mirdametinib for patients with NF1-PN and low-grade gliomas. Our DeFi clinical trial for adults with desmoid tumors and ReNeu clinical trial for patients with NF1-PN are now fully enrolled.
Desmoid tumors
Our Phase 3 DeFi clinical trial is ongoing to evaluate the efficacy and safety of nirogacestat as a monotherapy in adults with progressing desmoid tumors. Under a collaboration with Children’s Oncology Group (COG), a Phase 2 clinical trial is also evaluating nirogacestat as a monotherapy in children and adolescents with progressive, surgically unresectable desmoid tumors.
NF1-PN
Our Phase 2b ReNeu clinical trial is ongoing to evaluate the efficacy and safety of mirdametinib both in children 2 years or older and in adults with an inoperable NF1-PN.
Low-grade gliomas
A Phase 1/2 clinical trial is ongoing to evaluate the safety and efficacy of mirdametinib for the treatment of children, adolescents, and young adults with low-grade glioma (LGG).
Patient advocacy partners
Learn more from patient advocacy organizations
